

☒

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

Sheet 1 of 3

Application Number	10/783,451
Filing Date	02-20-2004
First Named Inventor	MICHEL DIB
Group Art Unit	10/14
Examiner Name	SPIVACK
Attorney Docket Number	ST99053 - US - CNT - 1



[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76
		Office ³	Number ⁴	Kind Code ⁵ (If known)				
PS	*	EP	0196132		KENNIS	10-01-1986		
PS	*	EP	0200322		PERREGAARD	11-05-1986		
PS	*	EP	0392959		PERREGAARD	10-17-1990		
PS	*	EP	0454436		CHAKRABARTI, ET AL	10-30-1991		
PS	*	EP	0529500		BARTLETT	08-19-1992		
PS	*	EP	0586191		DOUGLAS, ET AL	03-09-1994		
PS	*	EP	0733634		BUNNELL	09-25-1996		
PS	*	FR	2722099		SAUVEUR	01-12-1996		
PS	*	WO	94/25460		MESENS	11-10-1994		
PS	*	WO	96/30375		BUNNELL, ET AL	10-03-1996		

**Examiner
Signature**

Phillip Sivack

Date Considered

7/16/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

☒

+

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/783,451
				Filing Date	02-20-2004
				First Named Inventor	MICHEL DIB
				Group/Art Unit	1614
				Examiner Name	SP/NAK
Sheet	2	of	3	Attorney Docket Number	ST99053 - US - CNT - 1

[illegible][illegible]

Examiner Signature	Phyllis Spivack	Date Considered	7/16/05
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/088 (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/783,451
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	02-20-2004
		First Named Inventor	MICHEL DIB
		Group Art Unit	1614
		Examiner Name	SPINACK
		Attorney Docket Number	ST99053 - US - CNT - 1
Sheet	3	of	3

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PS	*	DIETCH, James T. et al., Aggressive Dyscontrol in Patients Treated with Benzodiazepines, J. Clin Psychiatry (1988, pp. 184-188, Volume 49:5).	
PS	*	OVERALL, John E. et al., The Brief Psychiatric Rating Scale, Psychological Reports, (1962, pp. 799-812, Volume 10).	
PS	*	SENNINGER, J. L. et al., La Risperidone Dans Le Traitement de L' Agressivite Des Schizophrenes, Ann. Med. Psychol. (1998, pp. 210-213, Volume 156 No. 3) ,	
PS	*	STIMMEL, Glen L., Benzodiazepines in Schizophrenia, Supplement to Pharmacotherapy (1996, pp. 148-151, Volume 16) ,	
PS	*	Vandel, et al, Drug extrapyramidal side effects, Eur. J. Clin. Pharmacol. (1999, pp. 659-665, Volume 55, No. 9).	
PS	*	WARNEKE, Lorne B., Benzodiazepines: Abuse and New Use, Can. J. Psychiatry (1991, pp. 194-205, Volume 36).	
PS	*	WOLKOWITZ, Owen M. et al., Benzodiazepines in the Treatment of Schizophrenia; A Review and Reappraisal, Am J Psychiatry (1991), pp. 714-726, Volume 148:6) .	
PS	*	ZINI, R et al., The Influence of Various Drugs on the Binding of Tianeptine to Human Plasma Proteins, International Journal of Clinical Pharmacology, Therapy and Toxicology (1991, pp. 64-66, Volume 29 No. 2).	

Examiner Signature	Phyllis Spinack	Date Considered	7/16/05
-----------------------	-----------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.